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Abstract
Background: Due to these changes in kidney function, aging kidneys are more prone to drug-induced
impairments in renal properties. Diabetes has been associated with the declined kidney function and an elevated
risk of renal failure. The aim of this study is to compare kidney function and potentially nephrotoxic drug use
among home-dwelling older persons with or without diabetes.
Methods: A total of 259 persons with and 259 persons without diabetes and aged ≥65 years were randomly
selected to participate in a health examination with complete data gathered from 363 individuals (187 with
diabetes and 176 without diabetes). The estimated glomerular filtration rate (eGFR) was calculated using CKD-EPI
equation. Each participant was categorized based on the nephrotoxic profile of their medications.
Results: There were no differences in mean eGFR values (77.5 ± 18.8 vs. 80.5 ± 14.8 ml/min/1.73m2, p = 0.089) or in
the proportion of participants with eGFR < 60 ml/min/1.73m2 among persons with diabetes (16% vs. 10%, p =
0.070), compared to persons without diabetes. Potentially nephrotoxic drug use was similar between the groups.
The mean number of potentially nephrotoxic drugs was 1.06 ± 0.88 in those with and 0.97 ± 1.05 in those without
diabetes (p = 0.39).
Conclusions: The kidney function of older persons with diabetes does not differ from that of older persons
without diabetes and furthermore potentially nephrotoxic drug use seem to play only a minor role in the decline in
kidney function among home-dwelling persons in the Inner-Savo district.
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Background
The global prevalence of diabetes increased by 30.6%
during the period 2005–2015 [1]. In 2030, it is estimated
that 552 million people will have received a diagnosis of
diabetes and the rise is expected to be highest in the old-
est age groups [2]. In global terms, in conjunction with
hypertension, diabetes is the most common cause of
chronic kidney disease [3]. It has been associated with a
higher rate in the decline of kidney function and an ele-
vated risk of renal failure [4–8].
Even healthy aging causes structural and functional
changes in the kidneys and the number of nephrons de-
clines with the age [9]. For example, individuals aged 70
to 75 years have 48% fewer nephrons when compared to
persons aged 18 to 29 years [10]. The loss of nephrons
leads to a decline in the glomerular filtration rate (GFR).
Comorbidities such as hypertension and diabetes com-
bined with normal aging can lead to additional nephron
losses and nephrosclerosis as well as larger glomeruli [9].
Due to these changes in kidney function, aging kidneys
are more prone to drug-induced impairments in renal
properties [11–13]. There are reports that a number,
from 6% [14] to 19% [15], of community-acquired acute
kidney injuries (AKIs) were caused by nephrotoxic
drugs. There are changes in the pharmacokinetics of
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several drugs as a result of the altered kidney function
and therefore kidney function measurements are
strongly recommended when prescribing medications to
older persons [11–13, 16].
Method
Aim of the study
The societal burden of diabetes is rising, especially in
the oldest age groups but only a few studies have fo-
cused on the kidney function of older persons with dia-
betes and with their use of nephrotoxic drugs [6, 8, 17–
21]. Hence, the aims of this study were to compare kid-
ney function and use of potentially nephrotoxic drugs
occurring among older home-dwelling persons with or
without diabetes.
Study population
The research data of this cross-sectional study is part of
the data collected for the Inner-Savo Diabetes Mellitus
research (ISDM). The study population (N = 3093) con-
sisted of home-dwelling people aged 65 years and older
living in the Inner-Savo region in Finland. The electronic
patient records of the Inner-Savo primary health care
system were used in order to identify persons with a
diagnosis of diabetes (n = 540, diagnostic codes of E10;
type 1 diabetes mellitus and E11; type 2 diabetes melli-
tus) in accordance with International Classification of
Diseases (ICD-10) [22]. Two age and gender matching
controls were selected for each person diagnosed with
diabetes using primary health care system. In autumn
2015, health questionnaires were sent to a total of 1417
persons, i.e. 527 persons with diabetes and 890 persons
without diabetes. In all, 518 of the 1084 questionnaire
respondents (response rate 76.5%), of which 259 with
and 259 without diabetes, were randomly selected to
participate in a health examination. Exclusion criteria in-
cluded being permanently bedridden and hospitalized
along with those patients suffering from the terminal
stages of cancer or other terminal illnesses. Ultimately,
complete data was gathered from 187 persons with dia-
betes (type 1 diabetes n = 5, type 2 diabetes n = 182) and
176 persons without diabetes.
Measurements and tools
The standardized health examinations were conducted
by one physician (MK). Weight and height and waist cir-
cumference were measured and body mass index (BMI)
was calculated (weight/ height2) for each participant.
Orthostatic blood pressure was measured after resting in
a supine position for 10 min. Orthostatic blood pressure
was measured in the lying, sitting and standing positions
at times of one and three minutes by using an auto-
mated blood pressure monitor [23]. Blood pressure was
measured in the sitting position at the time of one
minute.
Routine laboratory tests were analyzed by Eastern
Finland Laboratory Centre (ISLAB). ISLAB has been li-
censed by the Finnish Accreditation Service. Liver, kid-
ney and thyroid gland function along with blood
glucose, lipid levels and inflammation marker were de-
termined (P-ALAT, P-Krea, P-Alb, U-Alb, fPGluk, B-
HbA1C, fP-Kol, fP-Kol-HDL, fP-Kol-LDL, fP-Trigly, S-
CRP). Comorbidities and the most common chronic dis-
eases were verified by the physician from the electronic
patient records and the total number of comorbidities
was calculated. Six comorbidities were verified; (1) ische-
mic heart disease, (2) heart failure, (3) arterial fibrillation
and flutter, (4) hypertensive disease, (5) cerebrovascular
diseases, and (6) diseases of arteries, arterioles and
capillaries.
The estimated glomerular filtration rate (eGFR) was
calculated by using Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) –equation [24]. The cal-
culated value was based on the participant’s plasma
creatinine concentration, age and gender. The eGFR was
used to evaluate each participant’s kidney function.
CKD-EPI has been found to have good accuracy also
when assessing the eGFR in obese people [25]. Addition-
ally, eGFR with Cockcroft-Gault equation was calculated
to evaluate kidney function observing the effect of
weight of the participants [26].
Renbase® database was used to determine detailed drug
dosing recommendations for different degrees of renal
failure. Renbase® was developed by Medbase Ltd. [27].
The drug dosing recommendations were classified into
four categories; A to D; the classification is presented in
Table 1. In addition, the degree of renal failure is subdi-
vided into four categories; mild to end-stage renal failure
(mild: 90–60 ml/min/1.73m2, moderate: 60–30ml/min/
1.73m2, severe: 30–15ml/min/1.73m2, end-stage: < 15
ml/min/1.73m2). The classification of renal failure is
consistent with the European Medicines Agency (EMA)
classification. Renbase® includes recommendations of
drug dosing and safety as well as further information
about the pharmacokinetics and nephrotoxicity of the
drug.
The drug use was collected by physician during health
examinations. The Pharmacological Risk Assessment
Online system (Pharao®) is a tool which can identify the
number of clinically significant drug adverse effect pro-
files; in this research project, it was used to identify po-
tentially nephrotoxic drugs (Additional file 1: Table S1).
The database was developed by co-operation between
experts from Sweden and Finland [28]. Pharao® is a data-
base listing the drug adverse effects developed by the
working group [29]. It contains nine general and severe
adverse effects of drugs and estimates overall risk scores
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in a scale of zero to three (Table 1). General and severe
adverse effects include nephrotoxicity, QT prolongation/
arrhythmia, seizures, sedation, bleeding, orthostatic
hypotension, constipation, serotonergic and anticholin-
ergic side effects.
Ethics approval
Each of the participants gave consent to take part in this
study and to allow access to personal data process by
signing an informed consent form. The Research Ethics
Committee of the Northern Savo Hospital District gave
an approving statement for the study.
Statistical analysis
Continuous variables were analyzed by using either a t-
test or a bootstrap type t-test, and categorical variables
were compared using chi-square or Fisher’s exact test
where appropriate. The bootstrap (10,000 replications)
method was used when the theoretical distribution of the
test statistics were unknown or in the case of a violation
of the assumptions (e.g. non-normality). The normality of
the variables was tested by using the Shapiro-Wilk W test.
The Stata 15.1, StataCorp LP (College Station, TX, USA)
statistical package was used for the analysis.
Results
A total of 363 home-dwelling persons participated in the
health examination and complete data was gathered
from 187 persons with and 176 persons without dia-
betes. The mean age of the participants was 74 years;
this was identical in both groups. The proportion of fe-
males varied between the groups, 34% (n = 60) of the
participants without diabetes and 49% (n = 92) of those
with diabetes were females. The clinical characteristics
of the participants are presented in Table 2. Persons
with diabetes had a higher body mass index and a larger
waist (p < 0.001). Systolic and diastolic blood pressures
were higher among persons without diabetes (p = 0.05
and p = 0.039). Smoking was more common in persons
without diabetes (p = 0.021).
There was a statistically significant difference in the blood
lipid profiles between the groups. Persons without diabetes
had higher levels of total cholesterol, high-density and low-
density lipoprotein (p = 0.005, p < 0.001, p = 0.002). The
total triglyceride level was higher among persons with dia-
betes (p < 0.001). Furthermore, persons with diabetes had a
significantly higher C-reactive protein value (p = 0.034). In
both groups, the most common comorbidity was hyperten-
sive disease; this occurred more frequently among persons
diagnosed with diabetes (p = 0.029).
There was no statistically significant difference between
the estimated glomerular filtration rates (eGFR) of the two
groups. The mean eGFR value using CKD-EPI equation
was 80.5 (±14.8) ml/min/1.73m2 in the control group and
77.5 (±18.8) ml/min/1.73m2 in the group diagnosed with
diabetes (p = 0.089). The number of the participants who
had eGFR less than 60ml/min/1.73m2 was higher in the
group diagnosed with diabetes (n = 30, 16%) than in the
control group (n = 17, 10%), but the difference was not
quite statistically significant (p = 0.070). The proportions of
the participants in different eGFR levels with or without
diabetes are presented in Fig. 1. In additional analyze using
Cockcroft-Gault equation for eGFR, the mean eGFR for
persons with diabetes 90.1mL/min (SD 35.5) and for per-
sons without diabetes 83.3mL/min (SD 27.2) (p = 0.042).
The mean number of potentially nephrotoxic drugs for
each participant was approximately 1.06 (±0.88, n = 187)
in the group diagnosed with diabetes and 0.97 (±1.05,
n = 176) in the control group (p = 0.39). Each participant
was categorized into a class (A, B, C or D) based on the
nephrotoxic profile of their medications by using the
Pharao® database (Table 3). In both groups, more than
90% of the participants were placed into class A, which
designates no increased risk for nephrotoxicity. Four
participants (1.11%) were in the classes C and D, which
indicates either a moderately or a highly increased risk
for nephrotoxicity. Three of them were in the class C,
Table 1 Classification categories and definitions in Pharao® and Renbase® [8–10]
Classification Definition
Pharao Renbase
A No known pharmacological or clinical basis
for an increased risk.
No need for dosage modification.
B There is a somewhat increased risk. The information is not available or the recommendation is estimated based on the
pharmacokinetic characteristics of the substance.
C There is a moderately increased risk. Modification of the dose or dosage interval is needed.
D There is a high risk. The use should be avoided.
0 No pharmacological effect. –
1 A mild pharmacological effect. –
2 A moderate pharmacological effect. –
3 A strong pharmacological effect. –
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two with and one without diabetes. One person without
diabetes was categorized into the class D. The mean
eGFR values were calculated for each class A to D based
on categorized participants. In class A, the mean eGFR
value using CKD-EPI equation was 79.1 (±16.8, n = 334)
ml/min/1.73m2. In the classes B, C and D, the mean
eGFR values were 77.6 (±18.4, n = 25), 82.4 (±28.2, n = 3)
and 62.9 (n = 1) ml/min/1.73m2, respectively.
Discussion
Our main findings were that there were no differences
in kidney function or in the use of potentially
nephrotoxic drugs among older home-dwelling persons
with or without diabetes. In those persons diagnosed
with diabetes, the mean eGFR value was not significantly
lowered nor was there any significant difference in the
proportion of people with eGFR less than 60ml/min/
1.73m2. In addition, only 1 % of the participants were
using drugs which are known to carry a moderately and
highly increased risk of nephrotoxicity. In additional
analyze using Cockcroft-Gault equation for eGFR, per-
son with diabetes had slightly higher mean eGFR than
persons without diabetes. However, the values catego-
rized as normal renal function for both groups.
Table 2 Clinical characteristics of the participants with or without diabetes
No diabetes
N = 176
Diabetes
N = 187
P-value
Physiological factors, mean (SD)
Body mass index, kg/m2 28 (5) 31 (6) < 0.001
Waist, cm
Male 97 (12) 107 (14) < 0.001
Female 94 (13) 104 (15) < 0.001
Blood pressure mmHg, mean (SD)
Systolic 156 (22) 151 (22) 0.050
Diastolic 90 (12) 87 (11) 0.039
Smoking, n (%) 24 (14) 12 (6) 0.021
Comorbidities, n (%)
Ischemic heart disease 29 (16) 44 (24) 0.094
Heart failure 3 (2) 4 (2) 0.76
Arterial fibrillation and flutter 22 (12) 32 (17) 0.22
Hypertensive disease 99 (56) 126 (67) 0.029
Cerebrovascular diseases 6 (4) 4 (2) 0.46
Disease of arteries, arterioles and capillaries 6 (3) 5 (3) 0.68
Laboratory values, mean (SD)
Cholesterol, mmol/l
Total 4.91 (1.01) 4.59 (1.13) 0.005
High-density lipoprotein 1.56 (0.44) 1.38 (0.42) < 0.001
Low-density lipoprotein 3.00 (0.84) 2.70 (1.01) 0.002
Total triglycerides, mmol/l 1.14 (0.51) 1.56 (0.73) < 0.001
Fasting plasma glucose, mmol/l 6.15 (3.75) 7.78 (2.41) < 0.001
HbA1c, mmol/l 37.4 (3.5) 49.3 (13.6) < 0.001
ALAT, U/l 22.9 (10.8) 26.8 (17.3) 0.099
P-Alb, g/l 40.4 (3.1) 39.9 (3.7) 0.16
U-Alb, mg/l 4.5 (11.9) 11.3 (38.0) 0.11
CRP, mg/l 2.2 (3.7) 3.4 (6.5) 0.034
Glomerular filtration rate
CKD-EPI, ml/min/1.73m2, mean (SD) 80.5 (14.8) 77.5 (18.8) 0.089
CKD-EPI, < 60ml/min/1.73m2, n (%) 17 (10) 30 (16) 0.070
SD standard deviation, HbA1c glycated hemoglobin, ALAT Alanine aminotransferase, P-Alb plasma albumin, U-Alb urine albumin, CRP C-reactive protein, CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration equation for estimated glomerular filtration rate
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In previous studies, diabetes has been associated with
a higher risk of renal failure and a higher rate of renal
function decline [4–8]. Moreover, Polonia et al. [17]
stated that a higher proportion of hypertensive persons
with diabetes had their eGFR value reduced by more
than 10% per year and furthermore, also they displayed
elevated incidences of moderate and severe renal failure,
in comparison with their hypertensive counterparts
without diabetes. In the present study, there was no dif-
ference in the proportion of people with eGFR less than
60ml/min/1.73m2 between the groups. In the study con-
ducted by Hobeika et al. [6], persons with diabetes did
not differ in their baseline eGFR values when compared
to their counterparts without diabetes, which is consist-
ent with the present study. The study population con-
sisted of persons diagnosed with hypertension with a
mean age of 69 years in both groups. Contrary to the re-
sults of the present study and those of Hobeika et al. [6],
Yokoyma et al. [8] reported that participants without
diabetes had lower baseline eGFR values. The mean age
of their study population was less than 65 years and per-
sons without diabetes had been more frequently diag-
nosed with hypertension, which could explain the lower
baseline eGFR value.
Older persons are more prone to drug-induced renal
impairment, because of the age-associated deterioration
in kidney function [11–13]. In this study, only one in
every hundred participants used drugs associated with a
moderately and highly increased risk of nephrotoxicity.
In a population-based study conducted by Breton et al.
[18], 13.3% of the participants were exposed to drugs
which were either contraindicated or would require dos-
age adjustment, when the kidney function is insufficient.
The mean number of nephrotoxic drugs per participant
was 1.2 ± 0.6. In the present study, the mean numbers of
the potentially nephrotoxic drugs were approximately
1.06 and 0.97 drugs per person with and without dia-
betes, respectively. In three studies investigating Austra-
lian and American community-dwelling older persons
and nursing home residents, 6–28% had been prescribed
drugs which were either contraindicated or required
dosage adjustments due to their kidney function [19–
21]. In our previous study, one the most clinically rele-
vant drug-drug interactions concerned NSAID and anti-
hypertensives such as ACE-inhibitors, combination that
has also increased risk of nephrotoxicity [30].
The mean number of potentially nephrotoxic drugs
and proportion of persons who used contraindicated or
dosage adjustment requiring drugs were smaller here
than in the previous studies. Due to the database used in
this study, the numbers of drugs categorized as being
nephrotoxic are probably less when compared to the
other publications [18–21]. For example, there is one
obvious difference from the report of Breton et al. [18];
the Pharao® database does not classify diuretics,
angiotensin-receptor blockers and angiotensin-
converting enzyme inhibitors as nephrotoxic drugs. In
fact, drugs acting through the renin-angiotensin-
aldosterone system have been shown to be renoprotec-
tive in adults and are recommended for patients with
both diabetes and hypertension [31–34]. However, it
should be noted that those studies were not performed
in older participants. Due to the lack of evidence and
the paucity of studies conducted in older participants,
the categorization of nephrotoxic drugs used in the
Pharao® database may be viewed as acceptable [35].
Hedna et al. (2019) reported high specificity and conse-
quent usefulness of Pharao® database as screening tool.
However, further studies was recommended to further
study sensitivity in relation to dosage information [36].
Fig. 1 The proportions of the participants with or without diabetes
subdivided according to their eGFR levels (CKD-EPI
equation, ml/min/1.73 m2)
Table 3 Number of participants in the different nephrotoxicity
classes
Nephrotoxicity Number of participants Total
n (%)No diabetes
n (%)
Diabetes
n (%)
A 162 (92.05) 172 (91.98) 334 (92.01)
B 12 (6.82) 13 (6.95) 25 (6.89)
C 1 (0.57) 2 (1.07) 3 (0.83)
D 1 (0.57) 0 (0.00) 1 (0.28)
Total 176 (100) 187 (100) 363 (100)
A = No need for dosage modification; B = The information is not available or
the recommendation is estimated based on the pharmacokinetic
characteristics of the substance; C =Modification of the dose or dosage
interval is needed; D = The use should be avoided
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The strengths of this study are its population-based study
sample, which characterizes older home-dwelling primary
care patients diagnosed with diabetes, along with the high
questionnaire response and health examination participa-
tion rates. On the other hand, the study population origi-
nated from one primary care district and therefore a direct
generalization cannot be made at even the national level.
There are some limitations; the study subjects were
identified from the electronic patient records three
months before the questionnaires were dispatched, thus
the study population could not include persons with re-
cent onset of diabetes. Furthermore, due to the cross-
sectional nature of this study, we were not able to assess
the annual reduction in kidney function. The study
population consisted of home-dwelling older persons di-
agnosed with diabetes. It is conceivable that those per-
sons whose eGFR had declined by more than 10% per
year were no longer able to live at home and therefore
they could have been under-represented in the present
study population. Persons with diabetes usually have
regular health care visits to ensure good management of
their disease. This can be seen in the results; the partici-
pants diagnosed with diabetes had lower blood pressure
and better cholesterol values, than persons without dia-
betes. In the present study, we were not able to include
the dosage information and the used databases do not
have a possibility for the dosage assessment.
Nevertheless, more studies should be conducted to de-
termine the role of diabetes in the kidney function of
older individuals. Changes in kidney function should be
measured over time and compared with different age-
subgroups. Therefore, large enough sample sizes should
be used to able the subgroup analysis. In addition, more
population-based studies should be conducted in older
persons to determine their exposure to inappropriate
drugs with dosage information and association with the
declines occurring in kidney function.
Conclusion
The results of this study indicate that the kidney func-
tion of older home-dwelling persons with diabetes does
not differ from that of older persons without diabetes
and furthermore that use of potentially nephrotoxic
drugs play only a minor role in the in the worse renal
function of these individuals.
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